LIVE
LIVE GMP
Shellz India Ltd₹+17·Tonbo Imaging India Ltd₹+520·Zetwerk Manufacturing Business Ltd₹+8·Bonfiglioli Transmissions Ltd₹+128·Sahajanand Medical Technologies Ltd₹+35·Jio Platforms Ltd₹+220·Paras Healthcare Ltd₹+95·Ravita Engineering Services Ltd₹+3·Fusion CX Ltd₹+5·HD Fire Protect Ltd₹+80·Vaibhav Vyapaar Ltd₹0·R.K.Fashion Accessories Ltd₹0·Vishal Nirmiti Ltd₹+8·Nityas Gems & Jewellery Ltd₹+1·Paramount Syntex Ltd₹0·Acme India Industries Ltd₹+47·TNA Solutions Ltd₹+10·Shellz India Ltd₹+17·Tonbo Imaging India Ltd₹+520·Zetwerk Manufacturing Business Ltd₹+8·Bonfiglioli Transmissions Ltd₹+128·Sahajanand Medical Technologies Ltd₹+35·Jio Platforms Ltd₹+220·Paras Healthcare Ltd₹+95·Ravita Engineering Services Ltd₹+3·Fusion CX Ltd₹+5·HD Fire Protect Ltd₹+80·Vaibhav Vyapaar Ltd₹0·R.K.Fashion Accessories Ltd₹0·Vishal Nirmiti Ltd₹+8·Nityas Gems & Jewellery Ltd₹+1·Paramount Syntex Ltd₹0·Acme India Industries Ltd₹+47·TNA Solutions Ltd₹+10·
Goldline Pharmaceutical Ltd.
CLOSED
BSE SME
Bookbuilding IPO
Fresh capital only
Goldline Pharmaceutical IPO GMP
GREY MARKET
PREMIUM
₹
+ 26
+60% expected return
EST. LISTING
PRICE
₹69
Issue Price: ₹
43
Issue Price
₹43
Face Value
₹10
Lot Size
3,000 shares
Open Date
12 May 2026
Close Date
14 May 2026
Allotment
15 May 2026
Listing Date
19 May 2026
Exchange
BSE SME
Goldline Pharmaceutical IPO Details: Price, Dates & Financials
The Goldline Pharmaceutical IPO GMP strength score is 4 out of 10, which the dashboard rates as Moderate. The Goldline Pharmaceutical IPO is subscribed 598.69 times overall so far. Amounts are calculated at the upper price band of ₹43.
IPO Analytics Dashboard
LIVE
Goldline Pharmaceutical IPO GMP Insights
Valuation
Moderate
Goldline Pharmaceutical IPO GMP Strength Score
4
/ 10
Moderate
0–3 Weak
3–6 Moderate
6–8 Good
8–10 Strong
Goldline Pharmaceutical IPO Category-wise Subscription
Shares offered, bid & amount
| Category | Sub (x) | Offered | Bid For |
|---|---|---|---|
| QIB | 76.99 | 1,272,000 | 97,929,000 |
| NII / HNI | 1,664.45 | 390,000 | 649,134,000 |
| Retail (RII) | 874.20 | 900,000 | 786,780,000 |
| Market Maker | — | 138,000 | — |
| Total | 598.69 | 2,562,000 | 1,533,843,000 |
* Amount calculated at upper price band (₹43) · ** Total includes all investor categories
Goldline Pharmaceutical IPO Application Sizing
Minimum investment by category
Retail Investors ?
Min. Lots
2
Shares / Lot
6,000
Min. Investment
₹258,000
HNI Investors ?
Min. Lots
3
Min. Shares
9,000
Min. Investment
₹387,000
Goldline Pharmaceutical IPO Timeline & Key Dates
- 1 Initiation of Refund 18 May 2026
- 2 Credit of Shares to Demat 18 May 2026
Investor Interpretation
- Detailed subscription data will appear once the IPO opens.
This IPO has relatively lower interest or stretched valuation. Proceed with thorough research and caution.
Goldline Pharmaceutical IPO Subscription FAQs
Goldline Pharmaceutical IPO is subscribed 598.69x overall (Retail 874.20x, QIB 76.99x, NII/HNI 1,664.45x).
The retail (RII) portion of Goldline Pharmaceutical IPO is subscribed 874.20x.
Goldline Pharmaceutical IPO — QIB 76.99x, NII/HNI 1,664.45x.
In Goldline Pharmaceutical IPO, retail investors can apply for a minimum of 2 lot(s) (₹₹258,000); HNI/sNII minimum 3 lots (₹₹387,000).
Shares offered by category — QIB 1,272,000 shares, Retail 900,000 shares.
Subscription is shares bid for divided by shares offered in that category. If 10 lakh shares are offered and 50 lakh are bid for, the category is subscribed 5 times. Final numbers are confirmed after the bidding closes.
The NII category covers investors applying for shares outside the retail investor category, while HNI commonly refers to high-value investors within the NII category. Understanding the Goldline Pharmaceutical IPO's NII and HNI subscription levels helps investors assess demand for the Goldline Pharmaceutical IPO and overall investor interest.
GMP and IPO data are unofficial and for information only — not investment advice. Read the full disclaimer.